Recent 8-K filings for MMS

• May 7, 2026, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01 ◈ Earnings Releases

  Maximus Q2 EPS beats estimates, raises FY2026 guidance, authorizes $400M buyback

  Revenue $1.31B (vs $1.36B YoY); diluted EPS $1.80, adjusted $2.07 (vs $2.01 YoY).

• February 5, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Maximus Q1 adj EPS $1.85 beats prior $1.61; raises FY2026 guidance

  Revenue $1.35B (-4.1% YoY), in-line with expectations; GAAP EPS $1.70 vs $0.69, adj EPS $1.85 vs $1.61.

• November 20, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Maximus FY2025 revenue $5.43B (+2.4%), adj. EPS $7.36; FY2026 guidance adj. EPS $7.95-$8.25, rev $5.225B-$5.425B

  Full year revenue $5.43B (+2.4% YoY); organic growth 3.9% driven by U.S. Federal clinical programs.

• August 7, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Maximus Q3 FY2025 EPS $1.86 ($2.16 adj); raises full-year guidance

  Revenue $1.35B (+2.5% YoY); organic growth 4.3% led by U.S. Federal Services (11.4% growth).

• May 8, 2025, 7:59 PM ET earnings materiality 0.78 positive item 2.02item 9.01

  Maximus Q2 FY2025: EPS $1.69 (adj. $2.01); raises FY revenue/earnings guidance

  Revenue $1.36B (+1.0%); adjusted EPS $2.01 vs $1.57 YoY; organic growth 3.0%.

• February 6, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Maximus Q1 revenue up 5.7% to $1.40B, raises FY25 adjusted EPS guidance to $5.90-$6.20

  Adjusted diluted EPS $1.61 vs $1.34 YoY; GAAP EPS $0.69 includes $38M divestiture charges from Australia/South Korea sales.

• December 11, 2024, 6:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Maximus board authorizes $200M increase to stock purchase program

  Previous $200M authorization (June 2024) fully consumed; $171.4M remained as of Sep 30, 2024.

• November 26, 2024, 6:59 PM ET other material materiality 0.60 positive item 8.01item 9.01

  Maximus announces cancellation of CMS contract re-solicitation; existing contract continues through 2031

  CMS cancelled the CCO solicitation covering 1-800-MEDICARE and Federal Marketplace; no immediate re-solicitation planned.

• November 20, 2024, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Maximus FY2024 revenue up 8.2% to $5.31B; adj. EPS $6.11; FY2025 guidance $5.70-$6.00

  Full year FY2024 revenue $5.31B (+8.2% YoY); diluted EPS $4.99; adjusted diluted EPS $6.11.

• August 7, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Maximus Q3 FY2024 revenue $1.31B (+10.6%), adj. EPS $1.74, raises FY guidance for third time

  Revenue $1.31B (+10.6% YoY), diluted EPS $1.46, adjusted diluted EPS $1.74 (vs $0.50 and $0.78).

• June 12, 2024, 7:59 PM ET other material materiality 0.60 positive item 8.01item 9.01

  Maximus expands stock buyback program to $200M aggregate

  Board authorized $200M stock purchase program, including $6M remaining from prior authorization.

• May 8, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Maximus Q2 revenue up 11.7% to $1.35B, adjusted EPS $1.57; raises FY24 guidance

  Revenue $1.35B (+11.7% YoY); organic growth 12.6%; adjusted EPS $1.57 vs $0.81 prior year.

• February 7, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Maximus Q1 revenue $1.33B (+6.2%); raises FY24 EPS and FCF guidance

  Revenue $1.33B (organic +6.9%); diluted EPS $1.04, adjusted EPS $1.34 vs $0.65/$0.94 YoY.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event earnings

13 positive 0 negative 11 neutral

source · MMS on sec.gov